Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.
Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatici A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G. Palandri F, et al. Among authors: ibatici a. Leuk Res. 2018 Nov;74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5. Leuk Res. 2018. PMID: 30321784 Clinical Trial. No abstract available.
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.
Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M. Palandri F, et al. Among authors: ibatici a. Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108288 Free PMC article.
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F. Polverelli N, et al. Among authors: ibatici a. Hematol Oncol. 2018 Apr 6. doi: 10.1002/hon.2509. Online ahead of print. Hematol Oncol. 2018. PMID: 29624703
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R. Palandri F, et al. Among authors: ibatici a. Br J Haematol. 2018 Oct;183(1):35-46. doi: 10.1111/bjh.15497. Epub 2018 Jul 16. Br J Haematol. 2018. PMID: 30010187 Free article.
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎.
Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N. Palandri F, et al. Among authors: ibatici a. Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5. Semin Hematol. 2018. PMID: 30502854
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.
Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT, Ibatici A, Raiola AM, Frassoni F, De Stefano F, Verdiani S, Casarino L, Barosi G. Bacigalupo A, et al. Among authors: ibatici a. Bone Marrow Transplant. 2010 Mar;45(3):458-63. doi: 10.1038/bmt.2009.188. Epub 2009 Aug 31. Bone Marrow Transplant. 2010. PMID: 19718055
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L, Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatici A, Ciolli S, Coscia M, Sportoletti P, Murru R, Levato L, Gentile M, D'Arena G, Efremov DG, Tedeschi A, Scarfò L, Cuneo A, Foà R, Laurenti L. Innocenti I, et al. Among authors: ibatici a. Br J Haematol. 2019 Oct;187(1):e8-e11. doi: 10.1111/bjh.16123. Epub 2019 Jul 31. Br J Haematol. 2019. PMID: 31364153 Free article. No abstract available.
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report.
Cuneo A, Scarfò L, Reda G, Varettoni M, Quaglia FM, Marchetti M, De Paoli L, Re F, Pietrasanta D, Rigolin GM, Orsucci L, Ibatici A, Gattei V, Mauro FR, Trentin L, Laurenti L, Marasca R, Foà R. Cuneo A, et al. Among authors: ibatici a. Blood. 2020 Aug 6;136(6):763-766. doi: 10.1182/blood.2020006854. Blood. 2020. PMID: 32559271 Free PMC article. No abstract available.
74 results